Top Markets
#1 Nesa Nesa +814.51%
#2 Merlin's Seal BTC Merlin's Seal BTC +45.93%
#3 EXOD EXOD +22.78%
#4 QuantixAI QuantixAI +11.68%
#5 Fartcoin Fartcoin +10.37%
#6 Venom Venom +10.18%
#7 DOG•GO•TO•THE•MOON (Runes) DOG•GO•TO•THE•MOON (Runes) +9.13%
#8 PondCoin PondCoin +9.02%
#9 Movement Movement +8.72%
#10 Pons Pons +8.29%
Coin of the day
Nesa Nesa
Settings
Language
ENGLISH
Currency
USD
Theme
Reata Pharmaceuticals, Inc. Reata Pharmaceuticals, Inc.

Reata Pharmaceuticals, Inc.

RETA
Rank in Stocks #3251
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company... Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapies for individuals afflicted with severe or life-threatening illnesses. A key focus is bardoxolone methyl (often referred to as bardoxolone), which is currently undergoing Phase 3 clinical trials for two distinct conditions: chronic kidney disease (CKD) associated with Alport syndrome, and a specific type of pulmonary arterial hypertension linked to connective tissue diseases. Bardoxolone also has an offering for autosomal dominant polycystic kidney disease (ADPKD). The pipeline further includes omaveloxolone, currently in Phase II development for Friedreich's ataxia. Reata is also advancing Phase 2 studies for various other chronic kidney diseases, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, and focal segmental glomerulosclerosis, among others. Beyond these, the company's earlier-stage development includes RTA 901, aimed at neurological disorders, and RTA 1701, which holds potential for treating a spectrum of autoimmune, inflammatory, and fibrotic conditions. The company has established strategic partnerships, including an agreement with Kyowa Kirin Co., Ltd. for the development and commercialization of bardoxolone across various renal, cardiovascular, diabetes, and metabolic indications within a broad territory spanning Japan, China, Hong Kong, Macao, South Korea, Taiwan, and several Southeast Asian nations (Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia). Additionally, Reata collaborates with AbbVie Inc. to jointly research, develop, and commercialize second- and later-generation Nrf2 activators for all indications excluding renal, cardiovascular, and metabolic applications. Originally incorporated in 2002 as Reata Discovery, Inc., the company officially became Reata Pharmaceuticals, Inc. in May 2005. It is headquartered in Plano, Texas.
Share Price
$172.36
Last synced: 2023-09-26
Market Cap
$5.81B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Reata Pharmaceuticals, Inc. (RETA)

Category

Healthcare
Dividend history for Reata Pharmaceuticals, Inc. (RETA)
Reata Pharmaceuticals, Inc. (stock symbol: RETA) made a total of 0 dividend payments.
The sum of all dividends (adjusted for stock splits) is : 0.00
Dividend yield (TTM) : 0
Dividend payments for Reata Pharmaceuticals, Inc. (RETA) from 2026 to 2026
Annual dividend payments
Year Dividend (stock split adjusted) Change
Not enough data for the provided dates.
List of all dividend payments
Year Dividend Change
Not enough data for the provided dates.
Dividend payments for similar companies or competitors
Company Number of dividend payments Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
0.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
0.00%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
0.00%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
64.00%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00%
CH